Wegovy, the blockbuster weight-loss medication from Novo Nordisk A/S, eased heart failure symptoms for patients with diabetes in the latest large trial to support use of the drug to treat health conditions linked to obesity. Patients who took The drug reported less fatigue, less leg swelling, were less short of breath and were able to walk farther in six minutes than those who got a placebo. The wegovy patients also reported fewer serious medical problems.